The urogenital tract, specifically the vagina, urethra, bladder, trigone of the bladder, and pelvic floor muscles, contains estrogen receptors. Estrogen is needed for the health of these tissues and structures, a lack of which causes them to undergo atrophy (Castelo-Branco and Rostro, 2007; Nappi and Kokot-Kierepa, 2012). During the menopause transition and postmenopausal periods, women can experience a number of symptoms primarily due to estrogen depletion that include vasomotor and urogenital symptoms. Although vasomotor symptoms typically resolve over time, urogenital symptoms remain a persistent consequence of estrogen depletion (Winneker and Harris, 2011). Postmenopausal vaginal atrophy (PVA) is the term used to describe the group of urogenital symptoms that arise due to estrogen depletion and is also known as urogenital atrophy, vulvovaginal atrophy, and atrophic vaginitis (Mac Bride et al., 2010; Willhite and O’Connell, 2001). Approximately 10%–50% of postmenopausal women experience symptoms of vaginal atrophy, but only about 25% of them seek medical treatment (NAMS, 2007; Nappi and Kokot-Kierepa, 2012).
Cultural and social attitudes toward sexuality and aging are the primary determinants of the extent to which women report symptoms associated with PVA; therefore, the amount of PVA epidemiology data available in a given country varies considerably (Barlow et al., 1997). Today, women are living longer and spend approximately one third of their lives in the postmenopausal state. For this reason, there is evidence that in some regions, such as North America, attitudes towards the menopause transition are changing, and women are becoming more vocal about their menopause experience (Wright, 1998). Any changes in cultural and social norms that decrease the stigma surrounding menopause will likely lead to an increase in the diagnosed prevalence of PVA over time. The increase could exceed the projections of PVA prevalence found in this analysis.
- The Postmenopausal Vaginal Atrophy EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of postmenopausal vaginal atrophy in the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan). It includes a 10-year epidemiology forecast of PVA prevalent cases segmented by age (in five-year increments beginning at 50 years and ending at 79 years) and severity (mild, moderate, and severe) in the 7MM.
Reasons To Buy
- Develop business strategies by understanding the trends shaping and driving the global postmenopausal vaginal atrophy market.
- Quantify patient populations in the global postmenopausal vaginal atrophy market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and severity levels that present the best opportunities for postmenopausal vaginal atrophy therapeutics in each of the markets covered.
- Identify the percentage of postmenopausal vaginal atrophy cases that are mild, moderate, and severe
Table of Contents
1Table of Contents
1.1List of Tables
1.2List of Figures
3.1Risk Factors and Comorbidities
3.1.1Sexual inactivity increases symptoms of postmenopausal vaginal atrophy
3.1.2Smoking causes early menopause and exacerbates atrophic vaginal changes
3.1.3PVA prevalence is higher in women who have undergone cancer treatment
3.3.2Forecast Assumptions and Methods
3.3.3Sources Not Used
3.4Epidemiology Forecast of Postmenopausal Vaginal Atrophy
3.4.1Prevalent Cases of Postmenopausal Vaginal Atrophy
3.4.2Age-Specific Prevalent Cases of Postmenopausal Vaginal Atrophy
3.4.3Postmenopausal Vaginal Atrophy by Severity
3.5.1Conclusions on Epidemiological Trends
3.5.2Limitations of Analysis
3.5.3Strengths of Analysis
4.2About the Authors
4.2.3Global Director of Epidemiology and Clinical Trials Analysis
4.2.4Global Head of Healthcare
List of Table
List Of Tables
Table 1: Sources of Prevalence Data Used in the Epidemiology Forecast
Table 2: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, N, Select Years, 2012–2022
Table 3: 7MM, Calculated Total Prevalence of Postmenopausal Vaginal Atrophy, By Age, %,
Table 4: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, By Age, N, 2012
Table 5: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, By Severity, N (Row %), 2012
List of Chart
List Of Figures
Figure 1: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, N, Select Years, 2012–2022
Figure 2: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, By Age, N, 2012
Figure 3: 7MM, Prevalent Cases of Postmenopausal Vaginal Atrophy, By Severity, N (%), 2012
Make an enquiry before buying this Report
Please fill the enquiry form below.